Our mission

To help people live longer, healthier lives through scientifically proven health supplements.

Board of Directors

 

Matt Keys

CEO

Matt assumed the role of CEO at Cambridge Nutraceuticals in early 2023, transitioning from his previous position as Chief Marketing Officer. He has over two decades direct-to-consumer, multichannel retail and subscription-based business experience, and holds a particular passion for ecommerce and marketing. His previous roles include Head of Digital at Hotel Chocolat and Kite Eyewear, and consulting roles at Hobbs. Matt is dedicated to taking the company to new heights, building on a foundation of innovation and a commitment to best-in-class customer care.

Tim-Dye.jpg

Tim Dye

Non-executive director

Tim is a Cambridge graduate and serial entrepreneur who has successfully built and sold businesses across different sectors. He was Chief Executive and later Chairman of Ransom Naturals, which he built into one of the UK’s largest natural healthcare groups, before becoming a non-executive director at Abcam.

Tim became interim CEO of Cambridge Nutraceuticals in 2012, becoming Chairman in 2015 when Adam Cleevely was appointed CEO. Tim is also Chief Executive of Aurum Switzerland AG, a Zurich-based company investigating mycolicibacteria for use as immuno-modulatory agents. Until December 2019, he was Chairman of Thames Valley Harriers, one of the UK's top athletics clubs.

 
Jeff-Iliffe.jpg

Jeff Iliffe

Non-executive director

Jeff is a Chief Financial Officer with substantial experience on the boards of high-growth public and private companies in the technology and life science sectors. He was CFO of Abcam from 2007-2016, and oversaw MitoSciences, Ascent Scientific, Epitomics, Firefly BioWorks and AxioMx. He is also a Non-Executive Director of Treatt.

 
Jim-Warwick.jpg

Jim Warwick

Non-executive director

Jim has significant board-level experience in public and private companies, particularly in high-growth journeys from start-up to IPO and international operations. He was Chief Operating Officer of Abcam from 2003 to 2016, credited with scaling the company’s industry-leading IT and e-commerce developments. Jim was formerly Head of IT and Software at Analysis Ltd, and is a computer science graduate of Cambridge University. He’s also a Non-Executive Director at Quartix Holdings.

 
Adam-Cleevely.jpg

Adam Cleevely

Chairman

Adam has extensive experience in small and medium companies, with a focus on e-commerce. His previous roles include head of the Business Intelligence and Opportunities department at Abcam, Operations Director of Hubbub, an online food delivery business in London, and management consultant for Newton Europe. He has held a non-executive directorship at Bocca di Lupo, Soho’s acclaimed Italian restaurant, since it was founded. He holds an MEng in Engineering, Economics and Management from Oxford University.

 
Laura-Taylor.jpg

Laura Taylor

Non-executive director

A chartered accountant, Laura joined the Cambridge Nutraceuticals board in 2018 to play a key role in shaping the strategic future of the company and promoting its long term success. After an early career at Deloitte, Laura held Group Financial Controller roles at Xaar and Abcam, going on to lead the Investor Relations discipline. She most recently held the role of CFO at Congenica, where she was recognised as one of the top 50 female leaders in the UK life science sector for two years running.

 

What we’re talking about

Customer experiences, supplements for the season, and all our latest adventures

Explore the latest updates from the FutureYou Cambridge team.


Our journey

 

Cambridge Nutraceuticals has grown from strength to strength since its founding in ​the heart of the UK’s science hub in 2012, with close ties to Cambridge University. We’ve won the confidence of customers, investors​ and world-renowned research groups through our commitment to scientific excellence and customer service.

W​e create health supplements as they should be: with easy-to-absorb active ingredients and proven clinical benefits. If it isn’t supported by data, we won't sell it.

Our first product, Ateronon, was developed through £12 million in research funding and clinically ​tested at Cambridge University Hospital NHS Foundation Trust to ​prove its effectiveness.

In 2015, we used this rigorous scientific approach and our partnerships with leading research institutions to ​launch our FutureYou Cambridge range of health supplements.

Every FutureYou Cambridge product is founded on world-class academic expertise and manufactured using ​the highest quality ingredients. Turmeric+, the most popular of our joint health supplements, is now supported by 30 published studies and has been the focus of significant media coverage.

As we grow, people remain at the heart of everything we do – not only our customers but employees, suppliers and investors too – building trust and enduring relationships through a commitment to quality, openness and award-winning customer service.